|  |  |
| --- | --- |
| **Table S4. Detailed characteristics of the patients analyzed by irGEP (*n* = 72)** | |
| **Characteristic** | **No. of patients (%)a** |
| Median age (range), years | 67 (35–95) |
| Sex |  |
| Male | 43 (60) |
| Female | 29 (40) |
| ECOG performance status |  |
| 0–1 | 42 (58) |
| 2 | 15 (21) |
| 3–4 | 8 (11) |
| Unknown (not recorded) | 7 (10) |
| Smoking historyb |  |
| Current or former | 43 (60) |
| Never | 22 (31) |
| Unknown (not recorded) | 7 (10) |
| Favorable subset | 15 (21) |
| Neuroendocrine carcinoma (NEC) | 4 (6) |
| Squamous carcinoma limited to cervical lymph nodes (HNC-like) | 7 (10) |
| Adenocarcinoma restricted to axillary lymph nodes in females (BC-like) | 1 (1) |
| Extragonadal germ cell tumor syndrome (GCT-like) | 1 (1) |
| Peritoneal carcinomatosis in females (PPC-like) | 2 (3) |
| Squamous carcinoma limited to inguinal lymph nodes (ACC-like) | 0 (0) |
| Single resectable metastatic carcinoma | 0 (0) |
| Unfavorable subset | 57 (79)**c** |
| Multiple lymph nodes only metastasis | 19 (33) |
| Histology |  |
| Squamous | 15 (21) |
| Adeno | 32 (44) |
| Undifferentiated | 18 (25) |
| Other | 7 (10)d |
| Abbreviations: irGEP, immune-related gene expression profiling; ECOG, Eastern Cooperative Oncology Group. | |
| aPercentages may not add up to 100 because of rounding. | |
| bCurrent smokers were defined as individuals who had smoked ≥100 cigarettes including at least one within the year prior to diagnosis; former smokers as those who had smoked ≥100 cigarettes but had quit >1 year prior to diagnosis; and never-smokers as those who had smoked <100 cigarettes. | |
| cA plausible primary site of origin was identified in one patient (primary differentiated thyroid carcinoma was identified after second-line chemotherapy in a patient with multiple bone metastases). | |
| dAdenosquamous, *n* = 1; neuroendocrine carcinoma, *n* = 4; not otherwise specified, *n* = 2. | |